Physician profile
Karen Roden
NPI 1225023781
$264,937.23
in general payments reported to CMS, 2019-2025
41 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47K · 2022: $35K · 2023: $61K · 2024: $55K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Travel and Lodging: $27K · Food and Beverage: $15K · Consulting Fee: $3,169 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,975.20 |
| Travel and Lodging | $27,167.05 |
| Food and Beverage | $14,881.22 |
| Consulting Fee | $3,168.75 |
| Education | $339.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $158,432.43 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Genentech USA, INC. | $49,531.28 | 2021-2025 | Xolair, Xofluza |
| Genzyme Corporation | $20,206.73 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $18,249.41 | 2021-2025 | Dupixent |
| Amgen INC. | $11,708.25 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $957.14 | 2021-2025 | |
| Genentech, INC. | $913.34 | 2021-2025 | Xolair |
| Glaxosmithkline, LLC. | $626.13 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $541.28 | 2021-2025 | Hizentra, Haegarda |
| Janssen Pharmaceuticals, INC | $349.59 | 2022-2023 | Spravato |
| Optinose US, INC. | $300.77 | 2024-2025 | |
| Grifols USA, LLC | $296.07 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Myriad Genetic Laboratories, INC. | $264.00 | 2023 | Myrisk |
| Axsome Therapeutics, INC. | $229.83 | 2025 | Symbravo, Auvelity |
| Blueprint Medicines Corporation | $197.49 | 2021-2025 | Ayvakit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Roden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.